St Georges’ University London and the Liverpool School of Tropical Medicine are working with Mologic to accelerate COVID-19 point-of-need test kits. The prototype tests, which unveil results within ten minutes, will be distributed to specialist laboratories in every continent for thorough assessment on performance before they are distributed to the public.
Producing a reliable COVID-19 diagnostic test has been a struggle for healthcare organisations, however, Mologic's test enables users to test themselves in a clinical setting or at home. Mologic will market the test to low-income environments, to ensure impacted countries have access to testing as well.
“St Georges’ University London and the Liverpool School of Tropical Medicine are working with Mologic to accelerate COVID-19 point-of-need test kits.“
Chief Scientific Officer and Co-founder of Mologic, Professor Paul Davis, stated: “Completion of the first prototypes is a significant step in Mologic’s development of a rapid diagnostic test for COVID-19 and we are proud of our team’s achievement in reaching this point so quickly while maintaining the most rigorous standards. Diagnostics are a critical weapon in the fight against this pandemic and once ready, this test will enable affordable, more accurate and earlier diagnosis of infection, limiting the spread of the disease.”
Anne-Marie Trevelyan, International Development Secretary, stated: “The UK has been at the heart of the global response to the coronavirus outbreak, investing heavily in the research and development of potential new tests and vaccines including the work of world-class scientists across the UK. It is enormously encouraging to see the progress the British based lab Mologic, funded by UK aid, has already made to develop a reliable test for the virus for use in the UK and around the world.”
A Senior Lecturer in Diagnostics for Infectious Disease at the Liverpool School of Tropical Medicine, Dr Emily Adams, stated: “We are extremely pleased to be working alongside Mologic and diaTROPiX on the evaluation and validation of rapid diagnostic tests for COVID-19. These tests could be a game-changer for diagnosis and follow up of patients both in hospital and in the community, allowing us to detect cases early and isolate patients and their families rapidly. Of course, in low resource settings, where we are starting to see cases, these are the only tests that are appropriate for use. We need to manufacture and deliver as soon as we possibly can.”See all the latest jobs in Medical Devices